Abstract
The present study was performed to elucidate the underlying mechanism of transitional cell tumors found in the carcinogenicity testing of topiroxostat, a xanthine oxidoreductase inhibitor, in which topiroxostat was orally given to F344 rats at 0.3, 1, and 3 mg/kg for 2 years. In the urinary bladder, transitional cell papillomas and/or carcinomas were seen in males receiving 0.3, 1, and 3 mg/kg (1/49, 3/49, and 10/50, respectively). In the kidney, transitional cell papillomas and/or carcinomas in the pelvis were seen in 2/50 males and 1/50 females receiving 3 mg/kg. In the mechanistic study by 52-week oral treatment with topiroxostat at 3 mg/kg to F344 male rats, with and without citrate, simple and papillary transitional cell hyperplasias of the urinary bladder epithelium were observed in 5/17 in the topiroxostat-alone treatment group, along with xanthine-induced nephropathy, in contrast to neither xanthine crystals nor lesions in urinary organs by co-treatment group with citrate. As for sex differences of urinary bladder tumors, the BrdU labeling index for epithelial cells of the urinary bladder by 5-week oral treatment with topiroxostat at 10 mg/kg to F344 rats was increased in males only, showing consistency with histopathological findings. Therefore, the present study indicates that transitional cell tumors induced by topiroxostat in rats were due to physical stimulation to transitional cells of xanthine crystals/calculi and provides that other factors were not implicated in this tumorigenesis. Furthermore, the present study suggests that such tumors do not predict for humans since topiroxostat-induced xanthine deposition is a rodent-specific event.
Similar content being viewed by others
References
Adamopoulos D, Vlassopoulos C, Seitanides B, Contoyiannis P, Vassiloulos P (1977) The relationship of sex steroids to uric acid levels in plasma and urine. Acta Endocrinol 85:198–208
Agresti A, Wackerly D, Boyett JM (1979) Exact conditional tests for cross-classifications: approximation of attained significance levels. Psychometrika 44:75–83
Agresti A, Mehta CR, Patel NR (1990) Exact inference for contingency tables with ordered categories. J Am Stat Assoc 85:453–458
Ashizawa N, Shimo T, Matsumoto K, Oba K, Nakazawa T, Nagata O (2006) Strain differences in the responsiveness between Sprague-Dawley and Fischer rats to nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor. Toxicol Appl Pharmacol 217:260–265
Ashizawa N, Shimo T, Matsumoto K, Taniguchi T, Moto M, Nagata O (2011) Establishment of simultaneous treatment model with citrate for preventing nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats. Drug Chem Toxicol 34:151–161
Cohen SM (1983) Pathology of experimental bladder cancer in rodents. In: Ryan GT, Cohen SM (eds) The pathology of bladder cancer. CRC Press Inc., Boca Raton FL, vol 2, pp 1–40
Cox DR, Oakes D (1984) Analysis of survival data. Chapman and Hall, London
European Medicines Agency (2008) CHMP Assessment report for Adenuric (febuxostat). Doc Ref: EMEA/258531
Fukushima S, Cohen SM (1980) Saccharin-induced hyperplasia of the rat urinary bladder. Cancer Res 40:734–736
Fukushima S, Murasaki G, Hirose M, Nakanishi K, Hasegawa R, Ito N (1982) Histopathological analysis of preneoplastic changes during N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder carcinogenesis in rats. Acta Pathol Jpn 32:243–250
Fukushima S, Tanaka H, Asakawa E, Kagawa M, Yamamoto A, Shirai T (1992) Carcinogenicity of uracil, a nongenotoxic chemical, in rats and mice and its rationale. Cancer Res 52:1675–1680
Hollander M, Wolfe DA (1999) Nonparametric statistical methods, 2nd edn. Wiley, New York
Masui T, Shirai T, Imaida K, Hasegawa S, Fukushima S (1988) Effects of urinary crystals induced by acetazolamide, uracil, and diethylene glycol on urinary bladder carcinogenesis in N-butyl-N-(4-hydroxybutyl)nitrosamine-initiated rats. Toxicol Lett 40:119–126
Nicholls A, Snaith ML, Scott JT (1973) Effect of oestrogen therapy on plasma and urinary levels of uric acid. Br Med J 1:449–451
Ogasawara H, Imaida K, Ishiwata H, Toyoda K, Kawanishi T, Uneyama C, Hayashi S, Takahashi M, Hayashi Y (1995) Urinary bladder carcinogenesis induced by melamine in F344 male rats: correlation between carcinogenicity and urolith formation. Carcinogenesis 16:2773–2777
Okumura M, Hasegawa R, Shirai T, Ito M, Yamada S, Fukushima S (1992) Relationship between calculus formation and carcinogenesis in the urinary bladder of rats administered the non-genotoxic agents, thymine or melamine. Carcinogenesis 13:1043–1045
Peto R, Pike MC, Day NE, Gray RG, Lee PN, Parish S, Peto J, Richards S, Wahrendorf J (1980) Guidelines for simple, sensitive significance for carcinogenic effects in long-term animal experiment: annex to: Long-term and short term screening assays for carcinogens: a critical appraisal. World Health Organization, Lyon, pp 311–426
Teijin Pharma Limited (2011) Common technical document for new drug application of febuxostat. Publishing Pharmaceuticals and Medical Devices Agency, Japan. http://www.info.pmda.go.jp/shinyaku/P201100023/index.html. Accessed 4 Oct 2011
Sakata T, Masui T, St John M, Cohen SM (1988) Uracil-induced calculi and proliferative lesions of the mouse urinary bladder. Carcinogenesis 9:1271–1276
Shibata M, Yamada M, Asakawa E, Hagiwara A, Fukushima S (1989) Responses of rat urine and urothelium to bladder tumor promoters: possible roles of prostaglandin E2 and ascorbic acid synthesis in bladder carcinogenesis. Carcinogenesis 10:1651–1656
Shimo T, Ashizawa N, Matsumoto K, Nakazawa T, Nagata O (2005) Simultaneous treatment with citrate prevents nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats. Toxicol Sci 87:267–276
Shimo T, Ashizawa N, Moto M, Matsumoto K, Iwanaga T, Nagata O (2009) FYX-051, a xanthine oxidoreductase inhibitor, induces nephropathy in rats, but not in monkeys. Toxicol Pathol 37:438–445
Shimo T, Ashizawa N, Moto M, Iwanaga T, Nagata O (2011) Study on species differences in nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor. Arch Toxicol 85:505–512
Shirai T, Ikawa E, Fukushima S, Masui T, Ito N (1986) Uracil-induced urolithiasis and the development of reversible papillomatosis in the urinary bladder of F344 rats. Cancer Res 46:2062–2067
Snedecor GW, Cochran WG (1989) Statistical methods, 8th edn. Iowa State University Press, Iowa
Yoshida M (1988) Exact probabilities associated with Tukey’s and Dunnett’s multiple comparisons procedures in imbalanced one-way ANOVA. J Japanese Soc Comp Statist 1:111–122
Acknowledgments
We would like to express cordial gratitude to Dr. Shoji Fukushima, Japan Bioassay Research Center, for his excellent diagnosis and advice concerning transitional cell tumors. We would be grateful to Dr. Atsushi Shiga, Biosafety Research Center, Foods, Drugs and Pesticides, for his appropriate histopathology. We also wish to thank Dr. Yoshiaki Tagawa, Sanwa Kagaku Kenkyusho Co. Ltd., for his corporation.
Conflict of interest
None declaration.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shimo, T., Moto, M., Ashizawa, N. et al. Xanthine crystals induced by topiroxostat, a xanthine oxidoreductase inhibitor, in rats, cause transitional cell tumors. Arch Toxicol 88, 1035–1042 (2014). https://doi.org/10.1007/s00204-014-1195-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-014-1195-9